Ep. 32 Alzheimer's Breakthrough? Recall Thinks Restoration Is Possible

What if an Alzheimer’s therapy did not just slow decline, but restored memory and physical health back to baseline?In this episode of Spark Time, we sit down with Dan Salain, President and CEO of Recall Therapeutics, and Dr. Atul Chopra, Co-founder and CSO, to unpack one of the boldest ideas in neuroscience today: RTX-100, a gene therapy designed to restore cognition and systemic health in Alzheimer’s disease. Dan and Atul walk us through the science behind targeting memory circuits rather than just clearing amyloid, how a liver-expressed protein naturally crosses the blood–brain barrier, and why their preclinical data show full recovery of associative, recognition, and spatial memory in advanced mouse models.We also explore the overlooked systemic side of Alzheimer’s cachexia, sarcopenia, frailty, UTIs, pneumonia and how RTX-100 appears to normalize body weight, muscle strength, endurance, and fluid balance alongside cognitive recovery. From serendipity in the lab to regulatory strategy and potential paths to market, this conversation opens up a very different vision for what treating Alzheimer’s and even aging itself could look like.